Belatacept-based immunosuppression in heart transplant recipients: A single center experience
Recipients treated with belatacept-based regimen exhibited a trend of reduced de novo DSA development compared to standard tacrolimus-based regimen controls. Larger studies are needed to evaluate the benefit of belatacept use in heart transplant populations.
Authors
- Wairimu Magua (ORCID: https://orcid.org/0000-0002-0718-6464)
- Emily M. Eichenberger (ORCID: https://orcid.org/0000-0002-2469-0638)
- A. Van Beuningen
- Geeta M. Karadkhele (ORCID: https://orcid.org/0000-0002-0267-9665)
- Christian P. Larsen (ORCID: https://orcid.org/0000-0001-6573-2649)
- Darlington D. Pobee
- Anna B. Morris (ORCID: https://orcid.org/0000-0002-6879-6370)
- Alanna A. Morris (ORCID: https://orcid.org/0000-0002-8033-3707)
- J. David Vega (ORCID: https://orcid.org/0000-0002-0101-1962)
- Alexis K. Okoh (ORCID: https://orcid.org/0000-0001-8890-3332)
- Maggie Wang
- Divya Gupta (ORCID: https://orcid.org/0000-0002-9879-8553)
Institutions
- Emory University (US)
Publication Details
- Journal
- JHLT Open
- Published
- 2025-05-22
- DOI
- https://doi.org/10.1016/j.jhlto.2025.100277
- Citations
- 2
- Primary Topic
- Renal Transplantation Outcomes and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 3.97
Funders
- Bristol-Myers Squibb
- CareDx
- Carlos and Marguerite Mason Trust
- Natera